- Home
- BLTE vs MBLY Comparison
BLTE vs MBLY Comparison
Compare BLTE & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLTE | MBLY |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.3B |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BLTE | MBLY |
|---|---|---|
| Price | $178.00 | $7.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 19 |
| Target Price | ★ $198.00 | $16.06 |
| AVG Volume (30 Days) | 140.8K | ★ 6.3M |
| Earning Date | 05-12-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,894,000,000.00 |
| Revenue This Year | N/A | $4.91 |
| Revenue Next Year | $492.11 | $13.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 14.51 |
| 52 Week Low | $53.60 | $6.47 |
| 52 Week High | $200.00 | $20.18 |
Technical Indicators
Market Signals| Indicator | BLTE | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 44.46 |
| Support Level | $167.80 | $6.47 |
| Resistance Level | $196.14 | $8.13 |
| Average True Range (ATR) | 8.07 | 0.40 |
| MACD | 2.81 | 0.08 |
| Stochastic Oscillator | 95.21 | 54.69 |
Price Performance
Historical ComparisonAbout BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.